Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone ...

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

The EXPErimental medicine Route To Success in ALS (EXPERTS-ALS) project aims to rapidly screen potential drugs for evidence that they can slow down damage to the nervous system occurring in people wit ...

we believe AMX0114 has the potential to be a treatment for ALS and other diseases,” Amylyx Chief Medical Officer Camille Bedrosian, M.D., said in the release. The investigational antisense ...

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

People may also refer to it as “tetraplegia.” However, a range of therapies are available to treat ALS symptoms. This includes medications that may help slow the progress of ALS, such as ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published.

Nader Yaghoubi, M.D., Ph.D., PathMaker’s Co-Founder and CEO, stated, “We are pleased to announce IRB approval for the CALM study, which allows us to commence enrollments shortly. Given the mechanisms ...

Individuals living with ALS are automatically eligible for Medicare when they start receiving Social Security benefits. Medicare should cover most diagnostics and treatments, but this depends on the ...

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032. Sporadic ALS Holds The Largest Market Share In The ...